To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Division Vote (Commons)
24 Nov 2025 - English Devolution and Community Empowerment Bill - View Vote Context
Tonia Antoniazzi (Lab) voted No - in line with the party majority and in line with the House
One of 302 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 57 Noes - 309
Division Vote (Commons)
20 Nov 2025 - Deferred Division - View Vote Context
Tonia Antoniazzi (Lab) voted Aye - in line with the party majority and in line with the House
One of 312 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 376 Noes - 16
Division Vote (Commons)
20 Nov 2025 - Telecommunications - View Vote Context
Tonia Antoniazzi (Lab) voted Aye - in line with the party majority and in line with the House
One of 312 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 376 Noes - 16
Division Vote (Commons)
19 Nov 2025 - Border Security, Asylum and Immigration Bill - View Vote Context
Tonia Antoniazzi (Lab) voted Aye - in line with the party majority and in line with the House
One of 306 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 326 Noes - 92
Written Question
Drugs: Health Hazards
Wednesday 19th November 2025

Asked by: Tonia Antoniazzi (Labour - Gower)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the safety of talc used in medical products.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicine and Healthcare products Regulatory Agency (MHRA) is the Government agency responsible for ensuring that medicines and medical devices work and are acceptably safe.

Additives in medicines, termed excipients, are required to comply with the standards laid down in pharmacopeial monographs and can only be included in medicinal products at levels that are considered to be safe.

The MHRA is aware of general concerns in relation to the presence of asbestos in talcum powder, however, pharmaceutical grade talc has strict controls on the presence of asbestos. The British Pharmacopeia monograph for Purified Talc states that “Talc derived from deposits that are known to contain associated asbestos is not suitable for pharmaceutical use”. Furthermore, testing is required to confirm the absence of asbestos.


Written Question
Drugs: Health Hazards
Wednesday 19th November 2025

Asked by: Tonia Antoniazzi (Labour - Gower)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the safety of talc in medicines.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicine and Healthcare products Regulatory Agency (MHRA) is the Government agency responsible for ensuring that medicines and medical devices work and are acceptably safe.

Additives in medicines, termed excipients, are required to comply with the standards laid down in pharmacopeial monographs and can only be included in medicinal products at levels that are considered to be safe.

The MHRA is aware of general concerns in relation to the presence of asbestos in talcum powder, however, pharmaceutical grade talc has strict controls on the presence of asbestos. The British Pharmacopeia monograph for Purified Talc states that “Talc derived from deposits that are known to contain associated asbestos is not suitable for pharmaceutical use”. Furthermore, testing is required to confirm the absence of asbestos.


Speech in Commons Chamber - Wed 19 Nov 2025
Oral Answers to Questions

"The Northern Ireland Affairs Committee has taken evidence from Lord Murphy on his review of the Windsor framework, which has made important recommendations that could support GB businesses moving goods to Northern Ireland. Will the Secretary of State update the House on his considerations on the Murphy review?..."
Tonia Antoniazzi - View Speech

View all Tonia Antoniazzi (Lab - Gower) contributions to the debate on: Oral Answers to Questions

Division Vote (Commons)
18 Nov 2025 - Northern Ireland Troubles Bill - View Vote Context
Tonia Antoniazzi (Lab) voted Aye - in line with the party majority and in line with the House
One of 310 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 320 Noes - 105
Division Vote (Commons)
18 Nov 2025 - Northern Ireland Troubles Bill - View Vote Context
Tonia Antoniazzi (Lab) voted No - in line with the party majority and in line with the House
One of 311 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 165 Noes - 327
Written Question
National Wealth Fund: Wales
Tuesday 18th November 2025

Asked by: Tonia Antoniazzi (Labour - Gower)

Question to the HM Treasury:

To ask the Chancellor of the Exchequer, what discussions she has had with the Welsh Government on enabling (a) hauliers and (b) coach operators in Wales to access the National Wealth Fund for investment in zero-emission vehicles and refuelling infrastructure.

Answered by James Murray - Chief Secretary to the Treasury

The National Wealth Fund is committed to ensuring the benefits of its investments are felt in all four nations of the UK. It is actively engaging with stakeholders in Wales, including with the Welsh Government and Wales Office, to identify opportunities for investment.

As set out in the Chancellor’s Statement of Strategic Priorities to the National Wealth Fund in March 2025, clean energy and transport are priority sectors, this includes supporting the transition to zero-emission vehicles and associated refuelling infrastructure.

The National Wealth Fund will continue to explore investible propositions that satisfy its investment principles.